Pharmacologic therapy for peripheral arterial disease and claudication

Journal of Vascular Surgery

Volumn 36, Issue 6, 2002, Pages 1283-1291

  Hiatt, William R ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATIN;

ARTERY DISEASE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CEREBRAL ARTERY DISEASE; CLAUDICATION; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; GRAFT REJECTION; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; KINESIOTHERAPY; LIMB ISCHEMIA; MORTALITY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; TREATMENT PLANNING; VASCULAR SURGERY;

EID: 0037003504     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2002.129654     Document Type: Review

References (103)

1. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71:510-5.
2. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley diabetes study. Circulation 1995;91:1472-9.
3. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study (CHS) Collaborative Research Group. Circulation 1993;88:837-45.
4. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
5. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999;47:1255-6.
6. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
7. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality, in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999;19:538-45.
8. Newman AB, Tyrrell KS, Kuller LH. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc 1997;45:1472-8.
9. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991;87:119-28.
10. Vogt MT, McKenna M, Anderson SJ, et al. The relationship between ankle-arm index and mortality in older men and women. J Am Geriatr Soc 1993;41:523-30.
11. Kannel WB, McGee DL, Castelli WP. Latest perspectives on cigarette smoking and cardiovascular disease: the Framingham study. J Cardiac Rehabil 1984;4:267-77.
12. Vogt MT, Cauley JA, Kuller LH, et al. Prevalence and correlates of lower extremity arterial disease in elderly women. Am J Epidemiol 1993;137:559-68.
13. Stewart CP. The influence of smoking on the level of lower limb amputation. Prosthet Orthot Int 1987;11:113-6.
14. Ameli FM, Stein M, Prosser RJ, et al. Effects of cigarette smoking on outcome of femoral popliteal bypass for limb salvage. J Cardiovasc Surg 1989;30:591-6.
15. Gardner AW. The effect of cigarette smoking on exercise capacity in patients with intermittent claudication. Vasc Med 1996;1:181-6.
16. Daughton D, Susman J, Sitorius M, et al. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. Arch Fam Med 1998;7:425-30.
17. Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis, JAMA 1994; 271:1940-7.
18. Hays JT, Croghan IT, Schroeder DR, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am J Public Health 1999;89:1701-7.
19. Berlin I, Said S, Spreux-Varoquaux O, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Phar Ther 1995;58:444-52.
20. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.
21. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs 2000;59:1007-24.
22. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand 1987;221:253-60.
23. Quick CRG, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg 1982;69(Suppl):S24-6.
24. Johansson J, Egberg N, Hohnsson H, et al. Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb 1993;13:1441-8.
25. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997;96:44-9.
26. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
27. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
28. Prevention of cardiovascular events and death with pravastatin in patients with coronary, heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group [comments]. N Engl J Med 1998;339:1349-57.
29. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333-5.
30. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
31. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
32. Frohlich ED, Tarazi KC, Dustan HP. Peripheral arterial insufficiency. A complication ofbeta-adrenergic blocking therapy. JAMA 1969;208:2471-2.
33. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151:1769-76.
34. Heintzen MP, Strauer BE. Peripheral vascular effects of beta-blockers. Eur Heart J 1994;15 Suppl C:2-7.
35. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
36. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979;241:2035-8.
37. Beach KW, Strandness DE. Arteriosclerosis obliterans and associated risk factors in insulin -dependent and non-insulin-dependent diabetes. Diabetes 1980;29:882-8.
38. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.
39. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
40. Valentine R, Kaplan HS, Green K, et al. Lipoprotein (a), homocysteine,and hypercoaguable states in young men with premature peripheral atherosderosis: a prospective, controlled analysis. J Vasc Surg 1996;23:53-63.
41. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated wirh an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998;18:133-8.
42. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
43. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
44. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease, JAMA 2001;285:2481-5.
45. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
46. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
47. Boger RH, Bode-Boger SM, Thiele W, et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-74.
48. Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-8.
49. Leng GC, Lee AJ, Fowkes FG, et al. Randomized controlled trial of antioxidants in intermittent claudication. Vasc Med 1997;2:279-85.
50. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:23-33.
51. Donaldson MC, Weinberg DS, Belkin M, et al. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. J Vasc Surg 1990;11:825-31.
52. Catalano M, Russo U, Libretti A. Plasma beta-thromboglobulin levels and claudication degrees in patients with peripheral vascular disease. Angiology 1986;37:339-42.
53. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients 1. BMJ 2002;324:71-86.
54. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antip[atelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
55. Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register 1998;63:56802-19.
56. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticiopidine Multicenter Study. J Int Med 1990;227:301-8.
57. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128:541-4.
58. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2000;CD001246.
59. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk ofischaemic events (CAPRIE). Lancet 1996;348:1329-39.
60. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with ciopidogrel. N Engl J Med 2000;342:1773-7.
61. Sachdev GP, Ohlrogge KD, Johnson CL. Review of the Fifth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy: outpatient management for adults. Am J Health Syst Pharm 1999;56:1505-14.
62. Yusuf S, Zhao F, Mehta SR. et al. Effects ofclopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
63. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment ofclaudication pain. A meta-analysis. JAMA 1995;274:975-80.
64. Nehlcr MR, Hiatt WR, Exercise therapy for claudication. Ann Vase Surg 1999;13:109-14.
65. Hiatt WR, Wolfel EE, Meier RH, et al. Superiority of treadmill walking exercise vs strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 1994;90:1866-74.
66. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-21.
67. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vase Surg 1996;23:104-15.
68. Coffman JD. Vasodilator drugs in peripheral vascular disease. N Engl J Med 1979;300:713-7.
69. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 982;104:66-72.
70. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30.
71. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent c[audication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999;159:337-45.
72. Kohda N, Tani T, Nakayama S, et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 1999;96:261-8.
73. Igawa T, Tani T, Chijiwa T, et al. Potentiation of anri-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990;57:617-23.
74. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact ofcilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21-6.
75. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50.
76. Money SR, Herd JA,Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-74.
77. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
78. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
79. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001;87:28D-33D.
80. Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995;26:1411-6.
81. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J. Am Coll Cardiol 1999;34:1618-24.
82. Brevetti G, Perna S, Sabba C, et al. Effect ofpropionyl-L-carnitine on quality of life in intermittent claudication. Am J Cardiol 1997;79:777-80.
83. Lievre M, Morand S, Besse B, et al. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Circulation 2000;102:426-31.
84. Collaborative overview of randomized trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994;308:159-68.
85. Minar E, Ahmadi A, Koppensteiner, Ret al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995;91:2167-73.
86. Ranke C, Creutzig A, Luska G, et al. Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin Invest Med 1994;72:673-80.
87. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the leg. N Engl J Med 1997;337:1726-31.
88. Samama CM, Gigou F, Ill P. Low-molecular weight heparin vs unfractionated heparin in fermorodistal reconstructive surgery: a multicenter open randomized study. Ann Vasc Surg 1995;9:S45-S53.
89. Sarac TP, Huber TS, Back MR, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998;28:446-57.
90. Arfvidsson B, Lundgren F, Drott C, et al. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990;159:556-60.
91. Kretschmer G, Herbst F, Prager M, et al. A decade of oral anticoagulation treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992;127:1112-5.
92. Edmondson RA, Cohen AT, Das SK, et al. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994;344:914-8.
93. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery, (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomized trial. Lancet 2000;355:346-51.
94. Johnson WC, Williford WO. Benefits, morbidity and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002;35:413-21.
95. Tangelder MJ, Lawson JA, Algra A, et al. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg 1999;30:701-9.
96. Hertzer NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984;199:223-33.
97. Eagle KA, Brundage BH, Chairman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. Circulation 1996;93:1278-317.
98. Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001;285:1865-73.
99. Krupski WC, Nehler MR, Whitehill TA, et al. Negative impact of cardiac evaluation before vascular surgery. Vasc Med 2000;5:3-9.
100. Raby KE, Brull SJ, Timimi F, et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. Anesth Analg 1999;88:477-82.
101. Pasternack PF, Grossi EA, Baumann FG, et al. Beta blockade to decrease silent myocardial ischemia during peripheral vascular surgery. Am J Surg 1989;158:113-6.
102. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341:1789-94.
103. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.